News from the Johns Hopkins Department of Surgery
Study shows that neoadjuvant immunotherapy combined with chemotherapy in patients with operable, non-small cell lung cancer can reduce the risk of recurrence of cancer or death.
Researchers in the Johns Hopkins Department of Surgery are conducting a first-of-its-kind study with the aim of converting patients who typically are not considered candidates for hyperthermic intraperitoneal chemotherapy surgery into candidates for the procedure.
Via collaboration among surgeons and gastroenterologists, Johns Hopkins patients receiving combined transoral incisionless fundoplication, or cTIF, could see better results compared with traditional treatments.
